Development of a new hazard scoring system in primary neuronal cell cultures for drug-induced acute neuronal toxicity identification in early drug discovery.

adverse effect (AE) hazard score system micro-electrode array (MEA) neuronal cells neuronal toxicity seizures

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2024
Historique:
received: 06 10 2023
accepted: 03 05 2024
medline: 14 6 2024
pubmed: 14 6 2024
entrez: 14 6 2024
Statut: epublish

Résumé

We investigated drug-induced acute neuronal electrophysiological changes using Micro-Electrode arrays (MEA) to rat primary neuronal cell cultures. Data based on 6-key MEA parameters were analyzed for plate-to-plate vehicle variability, effects of positive and negative controls, as well as data from over 100 reference drugs, mostly known to have pharmacological phenotypic and clinical outcomes. A Least Absolute Shrinkage and Selection Operator (LASSO) regression, coupled with expert evaluation helped to identify the 6-key parameters from many other MEA parameters to evaluate the drug-induced acute neuronal changes. Calculating the statistical tolerance intervals for negative-positive control effects on those 4-key parameters helped us to develop a new weighted hazard scoring system on drug-induced potential central nervous system (CNS) adverse effects (AEs). The weighted total score, integrating the effects of a drug candidate on the identified six-pivotal parameters, simply determines if the testing compound/concentration induces potential CNS AEs. Hereto, it uses four different categories of hazard scores: non-neuroactive, neuroactive, hazard, or high hazard categories. This new scoring system was successfully applied to differentiate the new compounds with or without CNS AEs, and the results were correlated with the outcome of

Identifiants

pubmed: 38873414
doi: 10.3389/fphar.2024.1308547
pii: 1308547
pmc: PMC11170107
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1308547

Informations de copyright

Copyright © 2024 Kreir, Putri, Tekle, Pibiri, d’Ydewalle, Van Ammel, Geys, Teisman, Gallacher and Lu.

Déclaration de conflit d'intérêts

All the authors were employed by company Janssen Research and Development, Janssen Pharmaceutical Companies of Johnson & Johnson.

Auteurs

Mohamed Kreir (M)

Global Toxicology and Safety Pharmacology, Preclinical Sciences and Translational Safety, Janssen Research and Development, Beerse, Belgium.

Dea Putri (D)

Statistics and Decision Sciences, Global Development, Janssen Research and Development, Beerse, Belgium.

Fetene Tekle (F)

Statistics and Decision Sciences, Global Development, Janssen Research and Development, Beerse, Belgium.

Francesca Pibiri (F)

Global Toxicology and Safety Pharmacology, Preclinical Sciences and Translational Safety, Janssen Research and Development, Beerse, Belgium.

Constantin d'Ydewalle (C)

Neuroscience Discovery, Janssen Research and Development, Beerse, Belgium.

Karel Van Ammel (K)

Global Toxicology and Safety Pharmacology, Preclinical Sciences and Translational Safety, Janssen Research and Development, Beerse, Belgium.

Helena Geys (H)

Statistics and Decision Sciences, Global Development, Janssen Research and Development, Beerse, Belgium.

Ard Teisman (A)

Global Toxicology and Safety Pharmacology, Preclinical Sciences and Translational Safety, Janssen Research and Development, Beerse, Belgium.

David J Gallacher (DJ)

Global Toxicology and Safety Pharmacology, Preclinical Sciences and Translational Safety, Janssen Research and Development, Beerse, Belgium.

Hua Rong Lu (HR)

Global Toxicology and Safety Pharmacology, Preclinical Sciences and Translational Safety, Janssen Research and Development, Beerse, Belgium.

Classifications MeSH